A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas.
Phase of Trial: Phase II
Latest Information Update: 08 Jul 2015
At a glance
- Drugs Belinostat (Primary)
- Indications Cutaneous T cell lymphoma; Peripheral T-cell lymphoma
- Focus Therapeutic Use
- Sponsors TopoTarget
- 26 Oct 2014 Status changed from completed to discontinued as study had accumulated sufficient data to allow a registration study in PTCL (PXD101-CLN-19), as reported by CliniclTrials.gov .
- 01 Sep 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 22 Dec 2009 Additional locations [France, Germany, Israel, Thailand] added as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History